Literature DB >> 3350836

Immunohistochemical localization of creatine kinase BB in primary breast cancer: correlation with estrogen receptor content.

G Scambia1, G Santeusanio, P B Panici, S Iacobelli, S Mancuso.   

Abstract

The brain-type (BB) isoenzyme of creatine kinase (CK) has recently been shown to be estrogen-regulated in human breast cancer cells in vitro. In this study we have correlated the presence of CK-BB, evaluated by immunoperoxidase procedures, with the estrogen receptor (ER) content in 35 primary breast cancers. Of 35 tumors examined, 66% revealed moderate to strong CK-BB immunoreactivity. Staining was exclusively located in the cytoplasm of neoplastic cells. A positive relationship was observed between CK-BB positivity and ER content with ER-rich tumors (greater than 50 fmoles/mg protein) showing a more intense immunoreactivity than ER-poor ones. The results indicate that CK-BB is estrogen-regulated in human breast cancer and suggest that evaluation of this enzyme may be of potential value for the detection of hormone responsive tumors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3350836     DOI: 10.1007/bf00390493

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

1.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

2.  Estrogen responsive creatine kinase in human breast cancer cells.

Authors:  G Scambia; V Natoli; P B Panici; G Sica; S Mancuso
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.

Authors:  G C Reiner; B S Katzenellenbogen
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

Review 4.  Steroid hormone receptors in breast cancer treatment strategy.

Authors:  W L McGuire
Journal:  Recent Prog Horm Res       Date:  1980

5.  Identification of the major component of the estrogen-induced protein of rat uterus as the BB isozyme of creatine kinase.

Authors:  N A Reiss; A M Kaye
Journal:  J Biol Chem       Date:  1981-06-10       Impact factor: 5.157

6.  Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-11-25       Impact factor: 5.157

7.  Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen.

Authors:  R Mortel; C Levy; J P Wolff; J C Nicolas; P Robel; E E Baulieu
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

8.  Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.

Authors:  M Namer; C Lalanne; E E Baulieu
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

9.  Enzyme induction by estrogen.

Authors:  A M Kaye
Journal:  J Steroid Biochem       Date:  1983-07       Impact factor: 4.292

10.  Estrogen-induced creatine kinase in the reproductive system of the immature female rat.

Authors:  S D Malnick; A Shaer; H Soreq; A M Kaye
Journal:  Endocrinology       Date:  1983-11       Impact factor: 4.736

View more
  3 in total

Review 1.  Creatine kinase in non-muscle tissues and cells.

Authors:  T Wallimann; W Hemmer
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

2.  Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.

Authors:  N Durany; J Joseph; O M Jimenez; F Climent; P L Fernández; F Rivera; J Carreras
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

3.  Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients.

Authors:  N Zarghami; M Giai; H Yu; R Roagna; R Ponzone; D Katsaros; P Sismondi; E P Diamandis
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.